[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2874325B1 - Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine - Google Patents

Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine

Info

Publication number
FR2874325B1
FR2874325B1 FR0408986A FR0408986A FR2874325B1 FR 2874325 B1 FR2874325 B1 FR 2874325B1 FR 0408986 A FR0408986 A FR 0408986A FR 0408986 A FR0408986 A FR 0408986A FR 2874325 B1 FR2874325 B1 FR 2874325B1
Authority
FR
France
Prior art keywords
pharmaceutical composition
compressor containing
gastric resistance
containing alfuzosin
resistance compressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0408986A
Other languages
English (en)
Other versions
FR2874325A1 (fr
Inventor
Gerard Alaux
Estelle Chouin
Nathalie Dufresne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2874325(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to FR0408986A priority Critical patent/FR2874325B1/fr
Priority to PE2005000906A priority patent/PE20060639A1/es
Priority to ARP050103428A priority patent/AR050696A1/es
Priority to JP2007526512A priority patent/JP5048492B2/ja
Priority to BRPI0514532-5A priority patent/BRPI0514532A/pt
Priority to MYPI20053859A priority patent/MY145832A/en
Priority to AU2005276307A priority patent/AU2005276307B2/en
Priority to MX2007001957A priority patent/MX2007001957A/es
Priority to CN2005800311527A priority patent/CN101022808B/zh
Priority to EP05798249A priority patent/EP1781295A1/fr
Priority to EA200700217A priority patent/EA012981B1/ru
Priority to UY29073A priority patent/UY29073A1/es
Priority to PCT/FR2005/002092 priority patent/WO2006021692A1/fr
Priority to KR1020077003897A priority patent/KR20070046124A/ko
Priority to CA2577361A priority patent/CA2577361C/fr
Priority to NZ553673A priority patent/NZ553673A/en
Priority to TW094128210A priority patent/TWI357329B/zh
Publication of FR2874325A1 publication Critical patent/FR2874325A1/fr
Publication of FR2874325B1 publication Critical patent/FR2874325B1/fr
Application granted granted Critical
Priority to IL181150A priority patent/IL181150A0/en
Priority to US11/675,712 priority patent/US20070190140A1/en
Priority to ZA2007/01443A priority patent/ZA200701443B/en
Priority to NO20071315A priority patent/NO20071315L/no
Priority to MA29756A priority patent/MA28862B1/fr
Priority to HK08101572.6A priority patent/HK1112575A1/xx
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR0408986A 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine Expired - Fee Related FR2874325B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR0408986A FR2874325B1 (fr) 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
PE2005000906A PE20060639A1 (es) 2004-08-19 2005-08-04 Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo
ARP050103428A AR050696A1 (es) 2004-08-19 2005-08-16 Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo
PCT/FR2005/002092 WO2006021692A1 (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
BRPI0514532-5A BRPI0514532A (pt) 2004-08-19 2005-08-17 composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo
MYPI20053859A MY145832A (en) 2004-08-19 2005-08-17 Pharmaceutical composition in the form of a gastric retention tablet containing an active ingredient
AU2005276307A AU2005276307B2 (en) 2004-08-19 2005-08-17 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
MX2007001957A MX2007001957A (es) 2004-08-19 2005-08-17 Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo.
CN2005800311527A CN101022808B (zh) 2004-08-19 2005-08-17 含有活性组分的胃滞留片剂的药物组合物
EP05798249A EP1781295A1 (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
EA200700217A EA012981B1 (ru) 2004-08-19 2005-08-17 Фармацевтическая композиция в форме таблетки для нахождения в желудке, содержащая активное вещество
UY29073A UY29073A1 (es) 2004-08-19 2005-08-17 Composicinn farmaceutica en forma de comprimido de recidencia gastrica conteniendo alfuzosine
JP2007526512A JP5048492B2 (ja) 2004-08-19 2005-08-17 活性成分を含有する胃貯留錠の形態の薬学的組成物
KR1020077003897A KR20070046124A (ko) 2004-08-19 2005-08-17 활성 성분을 함유하는 위-정체 정제 형태의 제약 조성물
CA2577361A CA2577361C (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
NZ553673A NZ553673A (en) 2004-08-19 2005-08-17 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
TW094128210A TWI357329B (en) 2004-08-19 2005-08-18 Pharmaceutical composition in the form of a gastri
IL181150A IL181150A0 (en) 2004-08-19 2007-02-04 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
US11/675,712 US20070190140A1 (en) 2004-08-19 2007-02-16 Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle
ZA2007/01443A ZA200701443B (en) 2004-08-19 2007-02-19 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
NO20071315A NO20071315L (no) 2004-08-19 2007-03-09 Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen.
MA29756A MA28862B1 (fr) 2004-08-19 2007-03-14 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
HK08101572.6A HK1112575A1 (en) 2004-08-19 2008-02-13 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408986A FR2874325B1 (fr) 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine

Publications (2)

Publication Number Publication Date
FR2874325A1 FR2874325A1 (fr) 2006-02-24
FR2874325B1 true FR2874325B1 (fr) 2006-10-20

Family

ID=34950702

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408986A Expired - Fee Related FR2874325B1 (fr) 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine

Country Status (23)

Country Link
US (1) US20070190140A1 (fr)
EP (1) EP1781295A1 (fr)
JP (1) JP5048492B2 (fr)
KR (1) KR20070046124A (fr)
CN (1) CN101022808B (fr)
AR (1) AR050696A1 (fr)
AU (1) AU2005276307B2 (fr)
BR (1) BRPI0514532A (fr)
CA (1) CA2577361C (fr)
EA (1) EA012981B1 (fr)
FR (1) FR2874325B1 (fr)
HK (1) HK1112575A1 (fr)
IL (1) IL181150A0 (fr)
MA (1) MA28862B1 (fr)
MX (1) MX2007001957A (fr)
MY (1) MY145832A (fr)
NO (1) NO20071315L (fr)
NZ (1) NZ553673A (fr)
PE (1) PE20060639A1 (fr)
TW (1) TWI357329B (fr)
UY (1) UY29073A1 (fr)
WO (1) WO2006021692A1 (fr)
ZA (1) ZA200701443B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ578204A (en) 2006-12-22 2012-05-25 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008102235A1 (fr) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Formulations d'alfuzosine à libération contrôlée
JP2008280251A (ja) * 2007-05-08 2008-11-20 Shin Etsu Chem Co Ltd 多層錠及びその製造方法
AU2009267052B2 (en) 2008-06-30 2013-07-11 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2011102506A1 (fr) * 2010-02-22 2011-08-25 第一三共株式会社 Préparation solide à libération prolongée pour usage oral
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US10569071B2 (en) 2015-08-31 2020-02-25 Ethicon Llc Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US10245034B2 (en) * 2015-08-31 2019-04-02 Ethicon Llc Inducing tissue adhesions using surgical adjuncts and medicants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DK0938318T3 (da) * 1996-08-29 2001-08-20 Sanofi Synthelabo Tablet med kontrolleret frigivelse af alfuzosinchlorhydrat
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
EA200300046A1 (ru) * 2000-06-23 2003-10-30 Тева Фармасьютикал Индастриес Лтд. Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881424B1 (en) * 2000-09-05 2005-04-19 Mionix Corporation Highly acidic metalated organic acid
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors

Also Published As

Publication number Publication date
NO20071315L (no) 2007-03-09
MX2007001957A (es) 2007-04-25
MA28862B1 (fr) 2007-09-03
TW200618802A (en) 2006-06-16
NZ553673A (en) 2010-10-29
CA2577361A1 (fr) 2006-03-02
AR050696A1 (es) 2006-11-15
EA012981B1 (ru) 2010-02-26
HK1112575A1 (en) 2008-09-12
CA2577361C (fr) 2013-10-01
PE20060639A1 (es) 2006-07-20
FR2874325A1 (fr) 2006-02-24
AU2005276307B2 (en) 2011-02-24
CN101022808B (zh) 2013-05-29
BRPI0514532A (pt) 2008-06-17
JP5048492B2 (ja) 2012-10-17
WO2006021692A1 (fr) 2006-03-02
AU2005276307A1 (en) 2006-03-02
IL181150A0 (en) 2007-07-04
TWI357329B (en) 2012-02-01
EP1781295A1 (fr) 2007-05-09
KR20070046124A (ko) 2007-05-02
UY29073A1 (es) 2006-03-31
CN101022808A (zh) 2007-08-22
EA200700217A1 (ru) 2007-08-31
MY145832A (en) 2012-04-30
ZA200701443B (en) 2008-05-25
JP2008509973A (ja) 2008-04-03
WO2006021692A8 (fr) 2007-04-12
US20070190140A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
IL181524A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL173527A0 (en) Pharmaceutical composition containing water soluble drug
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
IL233352A0 (en) RNA molecules and pharmaceutical preparations containing them and their uses
IL182427A (en) Sulphonil-preserved bicyclic compounds, including pharmaceutical preparations and their use in the manufacture of pharmaceuticals
IL174647A (en) Pyrazolopyridines and analogs thereof, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
IL173726A (en) Pharmaceutical compositions containing n-n-dihaloamino acids and their uses
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
FR2834896B1 (fr) Composition pharmaceutique orodispersible d'ivabradine
EP1663201A4 (fr) Utilisation des nouveaux composes 2-oxo-heterocycliques et des compositions pharmaceutiques les contenant
PL361364A1 (en) Peptide and pharmaceutical composition as well as their therapeutic applications
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
HK1094153A1 (en) Nasal pharmaceutical composition of piribedil
FR2859627B1 (fr) Composition cosmetique sous forme d'emulsion e/h
FR2857593B1 (fr) Composition pharmaceutique orodispersible d'un compose antithrombotique
GB0327742D0 (en) Novel uses of known drugs
FR2835748B1 (fr) Composition ophtalmique sous forme d'emulsion
UA10191S (uk) Етикетка медичного препарату «ксилат»
UA9011S (uk) Упаковка фармацевтичного засобу «кетозорал»
GB0309509D0 (en) Pharmaceutical compositions and their uses

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20150430